Chatanaka Miyo K, Diamandis Eleftherios P
Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.
Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada.
EJIFCC. 2024 Aug 8;35(2):132-135. eCollection 2024 Aug.
The majority of the high-grade serous ovarian cancer (HGSOC) cases are diagnosed late, preventing effective treatment and therapy. We examine the feasibility of using EVA (Early oVArian cancer), a new molecular test for early HGSOC detection.
Comparison of the advantages and disadvantages of EVA with previously reported ovarian cancer tests, including CA125, was made, and the positive and negative predictive values of the tests were calculated as a measure of usefulness in the clinic.
The positive predictive value of EVA and CA125 was 8.6% and 6.8% respectively, which was calculated based on the disease prevalence of 0.5%. The negative predictive value was 99.9% in both cases.
EVA and CA125 are unlikely to provide a meaningful population screening method for HGSOC in women at risk, since the predictive values would drive women not to perform these tests.
大多数高级别浆液性卵巢癌（HGSOC）病例在晚期才被诊断出来，这使得有效治疗受到阻碍。我们研究了使用EVA（早期卵巢癌）这种用于早期检测HGSOC的新分子检测方法的可行性。
将EVA与先前报道的包括CA125在内的卵巢癌检测方法的优缺点进行比较，并计算这些检测方法的阳性和阴性预测值，以此作为其在临床实用性的衡量指标。
基于0.5%的疾病患病率计算得出，EVA和CA125的阳性预测值分别为8.6%和6.8%。两种检测方法的阴性预测值均为99.9%。
EVA和CA125不太可能为有风险的女性提供一种有意义的HGSOC人群筛查方法，因为预测值会导致女性不进行这些检测。
